… current chemotherapy drugs and … cancers including non-small cell lung cancer. Based on
this literature review, we propose the use of these compounds along with chemotherapy drugs …

… agents with greater than 15% activity in non-small-cell lung … Therefore, it is imperative to
develop new active agents if clear … This review will focus on several new chemotherapy agents …

… smallcell lung cancer (SCLC) will be diagnosed in the United States thisyear. Combination
chemotherapy is the cornerstone of treatment … Clearly, new chemotherapy agents with novel …

… agents is abrogated in lung cancer cells and whether PUMA expression suppresses growth
of lung cancer cells and/or sensitizes lung cancer cells to chemotherapeutic agents and …

… The identification of new chemotherapeutic agents for the treatment of non-small cell lung
cancer should proceed in a structured, logical fashion. Agents should be evaluated on the …

… of ReoT3D and chemotherapeutic agents against human non-small cell lung cancer (NSCLC). …
In this study, we evaluated the oncolytic activity of ReoT3D in non-small cell lung cancer (…

… to subsequent treatment with chemotherapeutic reagents, … lung cancer cells, the present
study points to the combined use of telomerasespecific inhibitors and chemotherapeutic agents …

… chemotherapy in non-small cell lung cancers. The pessimism was largely derived from the
fact that alkylating agent… showed that cisplatin-based chemotherapy improved patient survival, …

… in response to chemotherapy in NSCLC, we employed the RNA interference technique to
knock down βIII-tubulin expression in two independent lung cancer cell lines that express this …

… For example, in lung tumors, … lung tissue to a variety of therapeutic agents. We hypothesized
that mechanical forces may affect the response of lung tumors to chemotherapeutic agents …